M Stanley: China AI Drug R&D Financing Accelerates, GENSCRIPT BIO Benefits from Wet Lab Demand

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Morgan Stanley released a research report stating that private financing for China's AI-aided drug discovery (AIDD) companies reached RMB15.8 billion in the first nine months of this year, representing a 312% YoY increase on an annualized basis, involving a total of 57 financing rounds. Investors remain selective, favoring leading platforms with molecular design capabilities.

The bank believes molecular design is relatively mature, while structured data and rapid experimental feedback help model training and validation. However, development capability remains more difficult to predict. AIDD is expected to raise drug development success rates from the current 6% to 8% to double-digit percentages, although clinical success remains the ultimate validation, and most AI-designed drug candidates are still in early-stage development.

As AIDD companies improve their ability to generate candidate binding molecules, demand is expanding from gene synthesis and protein expression to binding assays, functional validation and developability testing, creating opportunities for wet lab service providers such as GENSCRIPT BIO (01548.HK) +0.940 (+3.094%) Short selling $245.43M; Ratio 20.529% . The company expects AIDD revenue in 2027 to more than double from 2026. The bank maintains an "Attractive" industry outlook.

GENSCRIPT BIO (01548.HK) +0.940 (+3.094%) Short selling $245.43M; Ratio 20.529% closed at HKD31.32 today, up 3.09%, with trading volume of 37.8359 million shares and turnover of HKD1.195 billion. (da/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-09 16:25.)

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.